The Big Picture
Novo Nordisk's semaglutide generated over $25 billion in revenue in 2025. It is the most commercially successful diabetes and obesity drug in history. The expiry of its core compound patent in March 2026 is one of the biggest events in pharmaceutical access this decade.
But "patent expiry" doesn't mean the same thing everywhere. Different countries, different patents, different timelines.
Country-by-Country Timeline
| Region | Core Patent Status | Generic Availability |
|---|---|---|
| 🇮🇳 India | Expired March 2026 | Now available — ₹2,000–4,000/month vs ₹12,000+ branded |
| 🇨🇳 China | Expired March 2026 | Launching Q2 2026 — multiple domestic manufacturers |
| 🇧🇷 Brazil | Expired March 2026 | Generics filing with ANVISA — expected H2 2026 |
| 🇿🇦 South Africa | Expired March 2026 | Available through local distributors |
| 🇨🇦 Canada | Expired March 2026 | Generic filings underway — expected late 2026 |
| 🇪🇺 Europe | Extended to March 2031 (SPC) | Not before 2031 |
| 🇺🇸 United States | Protected until Dec 2031–2032 | Not before late 2031 (formulation + device patents) |
Why the US Is Different
While the core compound patent expired globally, Novo Nordisk holds additional US patents covering:
- Formulation patents — how semaglutide is stabilized in the pen injector
- Delivery device patents — the FlexTouch pen mechanism
- Method-of-use patents — specific dosing regimens for obesity (the '343 patent extends to December 2031)
- Combination patents — CagriSema and other co-formulations
These "patent thickets" are common for blockbuster drugs. Even after the active ingredient goes off-patent, the total product system remains protected. Generic manufacturers must engineer around every one of these to launch a true substitute.
Key insight: If you're in India, Brazil, South Africa, or Canada — affordable semaglutide is available now or within months. If you're in the US or Europe, you're looking at 2031–2032 at the earliest.
What Generic Semaglutide Looks Like
Generic semaglutide (technically a "biosimilar" since it's a peptide) won't be identical to Ozempic. Differences may include:
- Different pen device — since the FlexTouch is patented, generics use alternative injector designs
- Slightly different formulation — same active molecule, different stabilizers
- Different brand names — Semaglutide Injection (generic name) from manufacturers like Sun Pharma, Dr. Reddy's, Biocon
- Same efficacy — regulatory agencies require bioequivalence studies before approval
Price Impact
In markets where generics are launching, prices are dropping dramatically:
- India: Branded Ozempic: ₹12,000–15,000/month → Generic: ₹2,000–4,000/month (70–85% reduction)
- Brazil: Expected 50–60% reduction once generics are approved
- US: No change until 2031+ — Ozempic remains at ~$900–1,000/month without insurance
Medical Tourism Angle
The patent divergence creates a unique opportunity. Patients in the US and Europe — where semaglutide costs $900+/month — can access the same molecule in India or Brazil for a fraction of the price. This is legal for personal use in most jurisdictions.
However, quality assurance matters. Not all generic manufacturers are equal. Look for:
- WHO prequalification or US FDA ANDA filing
- GMP-certified manufacturing facilities
- Published bioequivalence data
- Cold-chain shipping capability (semaglutide requires refrigeration)
What This Means for Patients
- If you're in India/Brazil/South Africa/Canada: Talk to your doctor about generic semaglutide. Same molecule, dramatically lower cost.
- If you're in the US/Europe: No generics until 2031+. Your options are insurance coverage, manufacturer savings programs (Novo Nordisk offers them), or exploring medical tourism.
- For everyone: The wave of next-generation GLP-1 agonists (see our article on next-gen GLP-1 drugs) may offer even better options within 1–2 years.
Compare GLP-1 Costs Globally
See real prices for Ozempic and generic semaglutide across 40+ countries.
Compare Costs →